Cefpirome
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Summary
Cefpirome is an antibiotic indicated in the treatment of a wide variety of infections in the body.
- Generic Name
- Cefpirome
- DrugBank Accession Number
- DB13682
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved
- Structure
- Weight
- Average: 514.577
Monoisotopic: 514.109309224 - Chemical Formula
- C22H22N6O5S2
- Synonyms
- cefpiroma
- Cefpirome
- cefpiromum
- External IDs
- HR 810
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Gram-negative infections bacterial infections •••••••••••• •••••••••• ••••••• ••• •••••••• Treatment of Infections, gram-positive bacterial •••••••••••• •••••••••• ••••••• ••• •••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Cefpirome may decrease the excretion rate of Abacavir which could result in a higher serum level. Abciximab The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefpirome. Aceclofenac The risk or severity of nephrotoxicity can be increased when Aceclofenac is combined with Cefpirome. Acemetacin The risk or severity of nephrotoxicity can be increased when Cefpirome is combined with Acemetacin. Acenocoumarol The risk or severity of bleeding can be increased when Cefpirome is combined with Acenocoumarol. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Cefpirome sulfate BA5ALU2ZT9 98753-19-6 RKTNPKZEPLCLSF-QHBKFCFHSA-N
Categories
- ATC Codes
- J01DE02 — Cefpirome
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as cephalosporins. These are compounds containing a 1,2-thiazine fused to a 2-azetidinone to for a oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid moiety or a derivative thereof.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Lactams
- Sub Class
- Beta lactams
- Direct Parent
- Cephalosporins
- Alternative Parents
- N-acyl-alpha amino acids and derivatives / 2,4-disubstituted thiazoles / Pyridinium derivatives / 1,3-thiazines / 2-amino-1,3-thiazoles / Tertiary carboxylic acid amides / Heteroaromatic compounds / Secondary carboxylic acid amides / Amino acids / Azetidines show 13 more
- Substituents
- 1,3-thiazol-2-amine / 2,4-disubstituted 1,3-thiazole / Alpha-amino acid or derivatives / Amine / Amino acid / Amino acid or derivatives / Aromatic heteropolycyclic compound / Azacycle / Azetidine / Azole show 28 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- cephalosporin, thiadiazoles, cyclopentapyridine (CHEBI:3503)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- S72Q2F09HY
- CAS number
- 84957-29-9
- InChI Key
- DKOQGJHPHLTOJR-WHRDSVKCSA-N
- InChI
- InChI=1S/C22H22N6O5S2/c1-33-26-15(13-10-35-22(23)24-13)18(29)25-16-19(30)28-17(21(31)32)12(9-34-20(16)28)8-27-7-3-5-11-4-2-6-14(11)27/h3,5,7,10,16,20H,2,4,6,8-9H2,1H3,(H3-,23,24,25,29,31,32)/b26-15-/t16-,20-/m1/s1
- IUPAC Name
- 1-{[(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}-5H,6H,7H-cyclopenta[b]pyridin-1-ium
- SMILES
- [H][C@]12SCC(C[N+]3=C4CCCC4=CC=C3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C([O-])=O
References
- General References
- FDA Thailand: Romecef (Cefpirome) Powder [Link]
- External Links
- Human Metabolome Database
- HMDB0041852
- KEGG Drug
- D07649
- KEGG Compound
- C11199
- ChemSpider
- 4586396
- 27130
- ChEBI
- 3503
- ChEMBL
- CHEMBL65794
- Wikipedia
- Cefpirome
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data4 Completed Not Available Abscesses / Cysts 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, for solution 1.468 g Powder 1 G Injection, powder, for solution 1 g Powder 250 mg/1vial Powder 500 mg/1vial Injection, powder, for solution - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00721 mg/mL ALOGPS logP -1 ALOGPS logP -4 Chemaxon logS -4.9 ALOGPS pKa (Strongest Acidic) 2.67 Chemaxon pKa (Strongest Basic) 3.54 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 153.92 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 141.3 m3·mol-1 Chemaxon Polarizability 50.94 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0a59-1932400000-6547b6c109293e8f8d27 - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 233.825516 predictedDarkChem Lite v0.1.0 [M-H]- 214.356116 predictedDarkChem Lite v0.1.0 [M-H]- 207.62381 predictedDeepCCS 1.0 (2019) [M+H]+ 232.376516 predictedDarkChem Lite v0.1.0 [M+H]+ 212.348816 predictedDarkChem Lite v0.1.0 [M+H]+ 209.8311 predictedDeepCCS 1.0 (2019) [M+Na]+ 233.532916 predictedDarkChem Lite v0.1.0 [M+Na]+ 212.934716 predictedDarkChem Lite v0.1.0 [M+Na]+ 215.66228 predictedDeepCCS 1.0 (2019)
Drug created at June 23, 2017 20:46 / Updated at May 29, 2021 18:12